Anti IgLON5 antibody syndrome: management
Evidence-based neurology checklist on anti iglon5 antibody syndrome: management: Pathogenesis This is a tauopathy It is caused by IgG4 or IgG1 antibodies to IgLON5 IgLON5 is a neuronal cell adhesion protein HLA allele risk factors Pathology Magnetic resonance imaging (MRI) brain Other…
Pathogenesis
- This is a tauopathy
- It is caused by IgG4 or IgG1 antibodies to IgLON5
- IgLON5 is a neuronal cell adhesion protein
HLA allele risk factors
Pathology
Magnetic resonance imaging (MRI) brain
Other investigations
Treatment
Predictors of treatment response
References
- Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014; 13:575-586.
- Schröder JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm 2016; 4:e302.
- Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017; 88:1736-1743.
- Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 2017; 4:e385.
- Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016; 132:531-543.
- And 6 more. Subscribe to see the full list
